Mantle cell lymphoma: charting disease course across multiple treatment lines

  • Kumar A & al.
  • Blood Cancer J
  • 20 May 2019

  • curated by David Reilly
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Unmet treatment needs persist for patients with mantle cell lymphoma (MCL) with early treatment failure or who fail multiple lines of therapy.

Why this matters

  • This study is unique in its duration of modern longitudinal data.

Study design

  • Study to investigate outcomes with successive treatment lines in 404 patients with MCL newly diagnosed and followed from 2000 to 2014.
  • Funding: Memorial Sloan Kettering Cancer Center; George L. Ohrstrom Jr Foundation.

Key results

  • Median OS by treatment line:
    • First-line: 116.3 (95% CI, 99.1-145.9) months.
    • Second-line: 41.1 (95% CI, 31.1-54.5) months.
    • Third-line: 25.2 (95% CI, 17.9-33.8) months.
    • Fourth-line: 14.4 (95% CI, 9.2-22.0) months.
  • Median PFS by treatment line:
    • First-line: 47.4 (95% CI, 40.5-56.5) months.
    • Second-line: 14.0 (95% CI, 9.7-16.0) months.
    • Third-line: 6.5 (95% CI, 3.8-10.0) months.
    • Fourth-line: 5.0 (95% CI, 3.0-9.7) months.
  • Median PFS with late first-line treatment failure, 15.7 (95% CI, 13.4-21.0) months vs 9.7 (95% CI, 4.9-15.2) months with early first-line failure (P<.01>
  • Median OS with late first-line treatment failure, 70.4 (95% CI, 41.0-86.4) months vs 29.9 (95% CI, 26.4-41.1) months with early first-line failure (P<.01>

Limitations

  • Ibrutinib received approval in 2013.